Literature DB >> 6705429

Potential applications of free drug level monitoring in cardiovascular therapy.

R L Woosley, L A Siddoway, K Thompson, I Cerskus, D M Roden.   

Abstract

Cardiovascular drugs, as a class, have low therapeutic indices, but also have great therapeutic potential. Plasma concentration information is therefore often of value when using these drugs. Unfortunately, the total plasma concentration may not reflect the concentration of pharmacologically active free drug, since a number of factors including disease states, heparin anticoagulation, non-linear binding characteristics, and in vitro artefacts can affect the protein binding of these agents. This may also explain their poor dose-response relationships and great interindividual variability in plasma concentration data. Careful studies relating bound and free drug concentration to pharmacological response may provide the clinician with a better guide to therapy, and enhance the usefulness of these drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705429     DOI: 10.2165/00003088-198400091-00010

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  18 in total

1.  Spuriously low plasma propranolol concentrations resulting from blood collection methods.

Authors:  R H Cotham; D Shand
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

2.  Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.

Authors:  R E BALL; M SOKOLOW
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

3.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

4.  Pharmacokinetic and clinical implications of quinidine protein binding.

Authors:  E Woo; D J Greenblatt
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

5.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

6.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

7.  Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

Authors:  O Borgå; K M Piafsky; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

8.  The artifactual nature of heparin-induced drug protein-binding alterations.

Authors:  J E Brown; B B Kitchell; T D Bjornsson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

9.  Importance of blood-collection tubes in plasma lidocaine determinations.

Authors:  W W Stargel; C R Roe; P A Routledge; D G Shand
Journal:  Clin Chem       Date:  1979-04       Impact factor: 8.327

10.  Relation of ventricular premature beat suppression to serum quinidine concentraton determined by a new and specific assay.

Authors:  N H Carliner; M L Fisher; W G Crouthamel; P K Narang; G D Plotnick
Journal:  Am Heart J       Date:  1980-10       Impact factor: 4.749

View more
  1 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.